Sequential Revenue Growth
BioLife Solutions reported its fourth consecutive quarter of sequential revenue growth, with a 6% increase in cell processing platform revenue this quarter and a 43% increase compared to the third quarter of 2023.
Margin Expansion
Adjusted gross margin for Q3 2024 was 54%, up from 44% in the same period last year. Adjusted EBITDA margin increased to 20% from 6% last year.
Strategic Divestiture
The company announced the strategic divestiture of its SciSafe BioStorage business in a $73 million all-cash transaction, which will streamline operations and strengthen the balance sheet.
Financial Performance
GAAP operating loss for Q3 2024 was reduced to $1.6 million from $15.5 million in the prior year, and adjusted operating loss decreased to $600,000 from $8.3 million in Q3 2023.
Increased Revenue Guidance
The cell processing revenue guidance was modestly increased based on strong Q3 results and projected future performance.